ELDA: real-time functional drug profiling in acute lymphoblastic leukemia

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Pediatric acute lymphoblastic leukemia (ALL) has high cure rates, but relapse remains challenging due to biological and clinical heterogeneity.
• Current stratification methods for ALL treatment can be complicated by patient-specific variations.
• A functional, patient-specific tool is needed to identify effective drugs for ALL, especially in relapsed cases.

Purpose of the Study:

• To develop and validate a novel ex vivo drug screening platform for pediatric ALL.
• To assess the platform's ability to generate individualized drug response profiles.
• To evaluate the platform's potential for optimizing therapy selection in precision oncology.

Main Methods:

• Developed ELDA (Ex vivo Leukemia Drug Advisor), a platform using time-lapse microscopy.
• Co-cultured primary ALL cells with bone marrow stromal cells in a 3D matrix.
• Quantified viable cells using a custom image analysis algorithm to monitor real-time drug response.

Main Results:

• ELDA showed strong concordance with established cytotoxicity assays (MTT, Calcein-AM).
• Drug profiling of 25 pediatric ALL samples revealed distinct patient-specific sensitivity and resistance patterns.
• ELDA-predicted drug sensitivities (dexamethasone, vincristine) were validated in vivo, demonstrating translational relevance.

Conclusions:

• ELDA is a validated ex vivo drug screening methodology for pediatric ALL.
• The platform generates individualized drug response profiles, supporting precision oncology.
• ELDA can be used for preclinical evaluation of novel agents and drug combinations.